SCHEDULE: FMR LLC Discloses Stake in Tango Therapeutics

FMR LLC reports beneficial ownership of 6.9% of Tango Therapeutics Inc. common stock as of March 31, 2026.

Summary

• FMR LLC, along with its affiliates and subsidiaries (collectively, the "FMR Reporters"), has filed a Schedule 13G indicating beneficial ownership of 9,905,919 shares of Tango Therapeutics Inc. common stock.
• This holding represents approximately 6.9% of the total outstanding common stock of Tango Therapeutics Inc.
• The filing is dated March 31, 2026, and was submitted on May 5, 2026.
• Abigail P. Johnson, a Director, Chairman, and CEO of FMR LLC, is also noted as a significant owner of FMR LLC, with the Johnson family potentially forming a controlling group.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a major institutional player, but it does not provide operational or financial updates from Tango Therapeutics itself.

Positives

• FMR LLC, a significant institutional investor, has taken a notable stake in Tango Therapeutics Inc., potentially signaling confidence in the company's prospects.
• The filing indicates a substantial beneficial ownership of 6.9%, suggesting a material investment.

Negatives

• The filing does not contain any negative financial results or operational challenges for Tango Therapeutics Inc. itself, as it is a disclosure of ownership by FMR LLC.

Risks

• The filing does not explicitly mention any risks related to Tango Therapeutics Inc. The primary risk associated with this filing is the potential for FMR LLC to alter its holdings, which could impact Tango Therapeutics' stock price.
• As FMR LLC is a large investment manager, changes in its investment strategy or market conditions could lead to adjustments in its stake in Tango Therapeutics.

Future Outlook

The filing does not contain forward-looking statements or guidance from Tango Therapeutics Inc. It is a disclosure of beneficial ownership by FMR LLC.

Management Comments

• FMR LLC and its affiliates are filing this Schedule 13G to report their beneficial ownership of Tango Therapeutics Inc. common stock.
• Abigail P. Johnson, as a significant owner of FMR LLC, may be deemed to form a controlling group with other Series B shareholders.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake by a major institutional investor like FMR LLC in a biotechnology company like Tango Therapeutics Inc. often reflects a positive outlook on the company's research and development pipeline or its potential for future growth within the competitive biotech landscape.

Stakeholder Impact

• Shareholders of Tango Therapeutics Inc. may view the increased stake by FMR LLC as a positive signal, potentially leading to increased investor confidence.
• The market may interpret this filing as a sign of institutional support for Tango Therapeutics' business strategy and pipeline.

Next Steps

• FMR LLC will continue to hold its shares in Tango Therapeutics Inc. and may adjust its holdings based on market conditions and investment strategy.
• Tango Therapeutics Inc. will continue its operations and R&D activities as previously disclosed.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by an institutional investor and does not contain operational or financial results of Tango Therapeutics. Therefore, a 'hold' recommendation is appropriate, suggesting investors await further company-specific news or financial reports before making significant decisions.

Keywords

Tango Therapeutics, FMR LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Abigail P. Johnson, Investment Management